



U.S. SENATOR JIM BANKS VISITS ERADIVIR AND LOW LABS

NIH Director Jay Bhattacharya, M.D., Ph.D., Joined Senator Jim Banks and Chief Scientific Officer Philip Low, Ph.D., for Tour Highlighting Advances in Antiviral Drug Development

February 18, 2026

WEST LAFAYETTE, Ind. - Eradivir Inc., the leading clinical-stage biotech company developing antibody recruiting small molecules to treat disease, today hosted U.S. Senator Jim Banks (R-Ind.) at the company's headquarters and affiliated Low Labs facility. Senator Banks toured the site alongside Eradivir Chief Scientific Officer Philip Low, Ph.D., and National Institutes of Health Director Jay Bhattacharya, M.D., Ph.D.

During the visit, Senator Banks met with company leadership and researchers to learn more about Eradivir's innovative BAiT™ (Bispecific Antigenic immuno-Therapy) platform and its pipeline of antibody-recruiting small-molecule therapeutics targeting viral diseases, including influenza and RSV.

The tour highlighted the company's ongoing research and development efforts, as well as its contributions to advancing next-generation antiviral treatments.

"We were honored to welcome Senator Banks and NIH Director Dr. Bhattacharya to our facilities today," said Dr. Philip Low, Chief Scientific Officer of Eradivir. "This visit provided an important opportunity to showcase the groundbreaking work being done right here in Indiana to develop innovative antiviral therapies. Our BAiT platform represents a new approach to combating viral diseases and strengthening pandemic preparedness."

The visit underscored the importance of public-private collaboration in accelerating biomedical innovation and strengthening the United States' leadership in biotechnology and pandemic preparedness.

ABOUT ERADIVIR

Eradivir Inc. is a privately held, clinical stage biotech company developing antibody recruiting small molecules to treat disease. Using its proprietary BAiT™ (Bispecific Antigenic immuno-Therapy) platform, the company is advancing a pipeline of antibody-recruiting small molecules,

including lead therapeutic EV25 for influenza and EV148 for RSV, with additional candidates in the pipeline targeting multiple diseases. Eradivir's lead antiviral therapeutic EV25 has demonstrated safety, tolerability and significant reduction in viral loads and influenza symptoms in Phase 2a clinical trials. Eradivir's small molecule targeting technology was discovered in Dr. Philip Low's Purdue University Laboratory, and the company is headquartered in West Lafayette, Indiana. For more information about the company and its latest news, visit www.eradivir.com.

Media and Partner Contact

Martin Low

martin.low@eradivir.com